dacarbazine has been researched along with tamoxifen in 114 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 8 (7.02) | 18.7374 |
1990's | 52 (45.61) | 18.2507 |
2000's | 36 (31.58) | 29.6817 |
2010's | 18 (15.79) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
Brunner, KW; Cavalli, F | 1 |
Cavalli, F | 1 |
Albright, KD; Christen, R; Eastman, A; Howell, SB; Jones, JA; McClay, EF | 1 |
Buzaid, AC; Murren, J | 1 |
Bella, M; Boni, C; Buzzi, F; Calabresi, F; Canaletti, R; Ceci, G; Cocconi, G; Corgna, E; Costa, P; Tonato, M | 1 |
Guerry, D; Schuchter, LM | 1 |
Cruse, CW; Klein, CJ; Reintgen, DS; Saba, HI; Wells, KE | 2 |
Cocconi, G | 1 |
Glover, DJ | 1 |
Basile, M; Bennett, JM; Blumberg, N; Harris, J; Moskowitz, B | 1 |
Doane, LL; Gilewski, TA; Mitchel, B; Ramming, K; Richards, JM; Vogelzang, NJ | 1 |
Buzaid, AC; Durivage, HJ; Murren, JR | 1 |
Richards, JM | 1 |
Avril, MF | 1 |
Bellet, RE; Berd, D; Mastrangelo, MJ; McClay, EF; Sprandio, JD | 1 |
Bellet, RE; Berd, D; Mastrangelo, MJ; McClay, EF | 1 |
Karakousis, CP | 1 |
Moertel, CG | 1 |
Del Prete, SA; Forcier, RJ; LeMarbre, P; Maurer, LH; O'Donnell, J | 1 |
Feun, LG; Hurley, J; Liebmann, A; Moffat, F; Raub, WA; Richman, SP; Robinson, D; Savaraj, N | 1 |
Chmielowska, E; Pluzańska, A; Potemski, P | 1 |
Atzpodien, J; Chaitchik, S; Duensing, S; Franzke, A; Kirchner, H; Körfer, A; Lopez Hänninen, E; Poliwoda, H; Schomburg, A; Volkenandt, M | 1 |
Borus, T; Edwards-Prasad, J; Hernandez, C; Nelson, J; Prasad, KN; Robinson, WA | 1 |
Berd, D; Mastrangelo, MJ | 1 |
Atkins, MB; Ernest, ML; Fisher, RI; Kappler, K; Margolin, KA; Mier, JW; O'Boyle, KR; Sosman, JA; Sparano, JA; Weiss, GR | 1 |
McClay, EF; McClay, ME | 1 |
Becker, JC; Bröcker, EB; Klingert, S; Winkler, B | 1 |
Crowell, EB; Higa, GM | 1 |
Gore, ME; Lorentzos, A; McKeage, MJ | 1 |
Appino, A; Bernengo, MG; Bertero, M; Colonna, S; Doveil, GC; Fierro, MT; Novelli, M | 1 |
Chertoff, J; DelPrete, SA; Ernstoff, MS; Forcier, RJ; Lattanzi, SC; LeMarbre, PJ; Maurer, LH; Mott, L; O'Donnell, J; Tosteson, T | 1 |
Flaherty, LE; Fletcher, WS; Goodwin, JW; Liu, PY; Mitchell, MS; Sondak, VK; Stephens, RL; Walker, MJ | 1 |
Armitage, GR; Bennett, K; Bodurtha, AJ; Burdette-Radoux, S; Iscoe, NA; James, KW; Jensen, J; Lohmann, RC; McCulloch, PB; Quirt, IC; Rusthoven, JJ; Silver, HK; Verma, S; Zee, B | 1 |
Atzpodien, J; Kirchner, HH; Poliwoda, H | 1 |
Ogasawara, H; Sakagami, M; Seo, W | 1 |
Ang, PT; Tan, EH | 1 |
Saida, T | 1 |
Fefer, A; Gold, PJ; Thompson, JA | 1 |
Buzaid, AC; Poo, WJ; Schultz, MZ | 1 |
Byrd, DR; Fefer, A; Gold, PJ; Lindgren, CG; Markowitz, DR; Thompson, JA | 1 |
Flaherty, LE; Fletcher, WS; Liu, PY; Margolin, KA; Smith, JW; Sondak, VK; Sosman, JA; Unger, JM; Walker, MJ; Weiss, GR | 1 |
Barth, NM; Dillman, RO; Honeycutt, PJ; Schulof, R; Soori, G; Stark, JJ; Wiemann, MC | 1 |
A'Hern, RP; Atkinson, H; Constenla, DO; Dadian, G; Gore, ME; Johnston, SR; Moore, J; Riches, PG | 1 |
Atkins, MB; Blum, RH; Coates, AS; Falkson, CI; Ibrahim, J; Kirkwood, JM | 1 |
Bassères, N; Bizzari, JP; Bonerandi, JJ; Gérard, B; Grob, JJ; Richard, MA; Zarrour, H | 1 |
Berd, D; Mastrangelo, MJ; McClay, EF | 1 |
Atzpodien, J; Buer, J; Franzke, A; Ganser, A; Hoffmann, R; Kirchner, H; Lassmann, S; Müller, I; Neuber, K; Oevermann, K; Probst, M | 1 |
Busch, R; Dengler, R; Eger, G; Emmerich, B; Münstermann, U; Plewan, A | 1 |
Haisa, M; Hara, K; Kamikawa, Y; Kenzo, A; Naomoto, Y; Perdomo, JA; Taguchi, K; Tanaka, N; Yamatsuji, T | 1 |
Bernstein, Z; Drumea, K; Haim, N; Shklar, Z; Stein, ME; Steiner, M; Zalik, M | 1 |
Einhorn, JH; Hwu, P; Marincola, FM; Rosenberg, SA; Schwartzentruber, DJ; Seipp, CA; Steinberg, SM; Topalian, SL; White, DE; Yang, JC | 1 |
Agarwala, SS; Ferri, W; Gooding, W; Kirkwood, JM | 1 |
Jedrzejczak, WW | 1 |
Flaherty, LE; Fletcher, WS; Hersh, EM; Hutchins, LE; Liu, PY; Margolin, KA; Smith, JW; Sondak, VK; Sosman, JA; Unger, JM; Urba, WJ; Weiss, GR | 1 |
Ishikawa, M; Wada, T; Yamamoto, A; Yamazaki, N | 1 |
Creagan, ET; Dalton, RJ; Krook, JE; Long, HJ; Michalak, JC; Pitot, HC; Rowland, KM; Suman, VJ; Veeder, MH; Vukov, AM | 1 |
Agarwala, SS; Begg, CB; Chapman, PB; Destro, AN; Einhorn, LH; Ernstoff, MS; Houghton, AN; Kirkwood, JM; Meyers, ML; Panageas, KS; Saxman, S; Schuchter, LM | 1 |
Boasberg, PD; Cannon, M; Edwards, S; Essner, R; Fawzy, NW; Foshag, LJ; Fournier, P; Gammon, G; Guo, M; Johnson, TD; Kristedja, TS; Martin, MA; Morton, DL; O'Day, SJ; Stern, S; Weisberg, M | 1 |
Bajetta, E; Barduagni, L; Bernengo, MG; Bufalino, R; Cascinelli, N; Comella, G; Criscuolo, D; Del Vecchio, M; DelVecchio, M; Morabito, A; Queirolo, P; Sertoli, MR; Vecchio, S | 1 |
Ashcroft, L; Harper, P; Lee, SM; Lorigan, P; Middleton, MR; Owen, J; Thatcher, N | 1 |
Braybrooke, JP; Christodoulos, K; Ganesan, TS; Han, C; Harris, AL; Levitt, NC; O'Byrne, K; Propper, DJ; Talbot, DC | 1 |
Cognetti, F; Sega, FM; Serrone, L; Zeuli, M | 1 |
Eggermont, AM; Keilholz, U; Suciu, S | 1 |
Sauter, C | 1 |
A'Hern, RP; Ayliffe, MJ; Eisen, T; Gore, ME; Hill, ME; Johnston, SR; Moore, J; Riches, PG; Thomas, JM; Vaughan, MM | 1 |
Flaherty, LE; Philip, PA | 1 |
Church, C; DePriest, CB; Dillman, RO; Dobbs, TW; Ruben, RH; Schulof, R; Soori, G; Wiemann, MC | 1 |
Aversa, SM; Cetto, GL; Chiarion Sileni, V; Corti, L; Favaretto, AG; Medici, M; Monfardini, S; Nortilli, R; Paccagnella, A | 1 |
Atzpodien, J; Bröcker, EB; Fluck, M; Kamanabrou, D; Müller, I; Neuber, K; Neumann, C; Patzelt, T; Paul, E; Reitz, M; Rünger, TM; Schuler, G; von den Driesch, P | 1 |
Lichtman, SM; Skirvin, JA | 1 |
Ames, P; Boasberg, PD; Deck, R; Fournier, P; Gammon, G; Kim, H; Kristedja, TS; Martin, M; O'Day, SJ; Piro, L; Shinn, K; Wang, HJ | 1 |
Bernstein, Z; Drumea, K; Haim, N; Sklar, Z; Stein, ME; Steiner, M; Tsalic, M | 1 |
Li, Y; McClay, EF | 1 |
Aglione, S; Bajetta, E; Bernard-Marty, C; Buzzoni, R; Del Vecchio, M; Khayat, D; Nova, P; Rixe, O; Taillibert, S; Vitali, M | 1 |
Baldwin, A; Huang, Z; Jounaidi, Y; Waxman, DJ | 1 |
Acito, L; Bacchi, M; Beretta, M; Carlini, P; Cocconi, G; Di Sarra, S; Foladore, S; Gebbia, V; Maiello, E; Marchi, M; Passalacqua, R | 1 |
Dmitruk, A; Kozlowski, L; Ostrowska, K; Wojtukiewicz, MZ; Zacharski, LR | 1 |
Neville, F; Nystrom, ML; Oliver, RT; Shamash, J; Steele, JP | 1 |
Akimov, MA; Barchuk, AS; Gel'fond, ML; Gershanovich, ML | 1 |
Komorowski, AL; Mituś, J; Wysocki, WM | 1 |
Calvet, D; Delattre, JY; Janoray, P; Rojas-Marcos, I | 1 |
Eisen, TG; Lens, MB | 1 |
Bafaloukos, D; Bedikian, AY; Gogas, H | 1 |
Peterson, RA; Rostomily, RC; Scharnhorst, JD; Silbergeld, DL; Spence, AM | 1 |
Harting, MS; Kim, KB | 1 |
Feun, L; Hurley, J; Marini, A; Mazumder, A; Moffat, F; Savaraj, N | 1 |
Hoon, DS; Kitago, M; Koyanagi, K; Kuo, C; Martinez, SR; Milford, R; Mori, T; Nguyen, SL; O'Day, SJ; Takeshima, TL; Umetani, N; Vu, VD; Wang, HJ | 1 |
Fukunaga, T; Kageshita, T; Kojima, S; Ogawa, H; Ono, T; Sakamoto, T; Soejima, H; Sugamura, K; Sugiyama, S; Tanoue, T; Yoshimura, M | 1 |
Chen, TC; Gupta, V; Hofman, FM; Kardosh, A; Liebes, LF; Schönthal, AH; Su, YS; Wang, W | 1 |
Lau, TK; Li, RH; Mok, TS; Ng, PC; Tam, B; Tam, WH | 1 |
Ezumi, K; Ikeda, M; Monden, M; Nomura, M; Sekimoto, M; Takemasa, I; Yamamoto, H | 1 |
Hollingshead, MG | 1 |
Kawano, N; Kihara, Y; Kume, K; Otsuki, M; Syukuwa, K; Taguchi, M; Tashiro, M; Yamasaki, M; Yoshikawa, I | 1 |
Mori, K; Nakao, Y; Wada, R; Watanabe, M; Yamamoto, T | 1 |
Doi, H; Iizuka, H; Ishida-Yamamto, A; Ito, Y; Tsuji, H | 1 |
Bei, D; Meng, J; Youan, BB | 1 |
Amin, P; Cheston, S; Dhople, A; DiBiase, S; Flannery, T; Meisenberg, B; Patel, A; Patel, S | 1 |
Caroli, M; Carrabba, G; DI Cristofori, A; Lanfranchi, G; Menghetti, C; Rampini, P | 1 |
Böhmer, FD; Kirches, E; Mawrin, C; Pachow, D; Petermann, A; Wallesch, M; Wilisch-Neumann, A | 1 |
He, W; Liu, R; Yang, SH; Yuan, F | 1 |
Balça-Silva, J; do Carmo, A; Girão, H; Lopes, MC; Matias, D; Moura-Neto, V; Sarmento-Ribeiro, AB | 1 |
Ding, WX; Gu, L; Guo, XW; Huang, XE; Liu, YC; Yin, XX; Zhou, SB | 1 |
Balça-Silva, J; Canedo, NHS; Correia, AH; De Souza, JM; Do Carmo, A; Dubois, LG; Girão, H; Gonçalves, AC; Lopes, MC; Matias, D; Moura-Neto, V; Sarmento-Ribeiro, AB | 1 |
15 review(s) available for dacarbazine and tamoxifen
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[New substances in oncologic therapy].
Topics: Alkylating Agents; Altretamine; Antimetabolites, Antineoplastic; Cisplatin; Dacarbazine; Doxorubicin; Drug Evaluation; Drug Evaluation, Preclinical; Etoposide; Humans; Neoplasms; Nitrosourea Compounds; Razoxane; Tamoxifen; Vinca Alkaloids; Zinostatin | 1978 |
Chemotherapy for advanced malignant melanoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Evaluation; Humans; Immunologic Factors; Incidence; Interferon-alpha; Melanoma; Pilot Projects; Skin Neoplasms; Tamoxifen; Transplantation, Autologous | 1992 |
[Chemotherapy of malignant melanoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Interferons; Interleukin-2; Lomustine; Melanoma; Prognosis; Skin Neoplasms; Tamoxifen | 1988 |
Treatment of the carcinoid tumor and the malignant carcinoid syndrome.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Appendectomy; Appendiceal Neoplasms; Carcinoid Tumor; Cyclophosphamide; Dacarbazine; Dactinomycin; Doxorubicin; Embolization, Therapeutic; Female; Fluorouracil; Hepatic Artery; Humans; Hydroxyindoleacetic Acid; Ligation; Liver Neoplasms; Male; Malignant Carcinoid Syndrome; Middle Aged; Rectal Neoplasms; Streptozocin; Tamoxifen | 1983 |
Tamoxifen: is it useful in the treatment of patients with metastatic melanoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Drug Synergism; Humans; Melanoma; Tamoxifen; Treatment Outcome | 1994 |
[Treatment of malignant melanoma: recent advances and perspectives].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Melanoma; Nimustine; Skin Neoplasms; Tamoxifen; Vincristine | 1997 |
The Dartmouth Regimen: gone or going strong?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Clinical Trials as Topic; Dacarbazine; Humans; Melanoma; Tamoxifen | 1998 |
Biochemotherapy for melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Humans; Immunotherapy; Interferons; Interleukin-2; Melanoma; Mice; Tamoxifen | 2000 |
Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Complementary Therapies; Cytochrome P-450 Enzyme System; Dacarbazine; Etoposide; Humans; Idarubicin; Neoplasms; Tamoxifen; Temozolomide; Thalidomide; Topotecan | 2002 |
Systemic chemotherapy for the treatment of metastatic melanoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carmustine; Cisplatin; Clinical Trials as Topic; Dacarbazine; Humans; Melanoma; Nitrosourea Compounds; Paclitaxel; Tamoxifen; Taxoids; Temozolomide | 2002 |
Metastatic melanoma: chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Cisplatin; Clinical Trials as Topic; Cytokines; Dacarbazine; Genetic Therapy; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Paclitaxel; Tamoxifen; Taxoids; Thalidomide | 2002 |
Systemic chemotherapy in the treatment of malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Humans; Lomustine; Melanoma; Neoplasm Metastasis; Skin Neoplasms; Tamoxifen; Treatment Outcome; Vincristine | 2003 |
The role of taxanes in the treatment of metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Dacarbazine; Humans; Melanoma; Skin Neoplasms; Tamoxifen; Taxoids; Temozolomide; Treatment Outcome | 2004 |
Engineering nanomedicines for improved melanoma therapy: progress and promises.
Topics: Antineoplastic Agents; Carmustine; Cisplatin; Dacarbazine; Drug Delivery Systems; Humans; Melanoma; Nanomedicine; Tamoxifen | 2010 |
50 trial(s) available for dacarbazine and tamoxifen
Article | Year |
---|---|
[New substances in oncologic therapy].
Topics: Altretamine; Ancitabine; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Cisplatin; Clinical Trials as Topic; Dacarbazine; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Etoposide; Humans; Mitolactol; Nitrosourea Compounds; Razoxane; Remission, Spontaneous; Tamoxifen; Time Factors; Vinca Alkaloids; Zinostatin | 1978 |
Chemotherapy for advanced malignant melanoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Evaluation; Humans; Immunologic Factors; Incidence; Interferon-alpha; Melanoma; Pilot Projects; Skin Neoplasms; Tamoxifen; Transplantation, Autologous | 1992 |
Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Dacarbazine; Female; Humans; Male; Melanoma; Menopause; Middle Aged; Neoplasm Metastasis; Prospective Studies; Sex Factors; Survival Rate; Tamoxifen | 1992 |
Disseminated melanoma--is there a new standard therapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Melanoma; Neoplasm Metastasis; Tamoxifen | 1992 |
High-dose cisplatin with dacarbazine and tamoxifen in the treatment of metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Male; Melanoma; Tamoxifen | 1992 |
High-dose cisplatin with dacarbazine and tamoxifen in the treatment of metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Cisplatin; Dacarbazine; Drug Evaluation; Female; Hematologic Diseases; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Remission Induction; Skin Neoplasms; Tamoxifen | 1991 |
Phase II trial of recombinant interferon-alpha with BCNU, cisplatin, DTIC and tamoxifen in advanced malignant melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Female; Humans; Interferon Type I; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Tamoxifen | 1995 |
Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
Topics: Administration, Cutaneous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Infusions, Intravenous; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Skin Neoplasms; Tamoxifen; Treatment Outcome | 1995 |
Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Interleukin-2; Male; Melanoma; Middle Aged; Remission Induction; Tamoxifen | 1994 |
Therapy for metastatic melanoma: effective combination of dacarbazine, carmustine, cisplatin and tamoxifen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Soft Tissue Neoplasms; Tamoxifen | 1993 |
Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Sex Characteristics; Survival Rate; Tamoxifen | 1995 |
The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma. A phase II trial of the Southwest Oncology Group, (SWOG-8921).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Administration Schedule; Estrogen Antagonists; Female; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Remission Induction; Sex Factors; Tamoxifen | 1996 |
Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Disease-Free Survival; Double-Blind Method; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Rate; Tamoxifen | 1996 |
[Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Tamoxifen | 1996 |
[Chemohormonal therapy for malignant melanomas].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Estrogen Antagonists; Female; Head and Neck Neoplasms; Humans; Male; Melanoma; Middle Aged; Tamoxifen | 1996 |
Combination chemotherapy (dacarbazine, carmustine, cisplastin, and tamoxifen) in advanced melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Prognosis; Singapore; Skin Neoplasms; Survival Rate; Tamoxifen | 1996 |
Outpatient chemoimmunotherapy for the treatment of metastatic melanoma.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Skin Neoplasms; Tamoxifen; Treatment Outcome | 1997 |
A phase II study of interferon-alpha 2b with dacarbazine, carmustine, cisplatin and tamoxifen in metastatic melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Confidence Intervals; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Humans; Interferon alpha-2; Interferon-alpha; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Tamoxifen | 1997 |
Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunotherapy; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Interleukin-2; L-Lactate Dehydrogenase; Male; Melanoma; Middle Aged; Prognosis; Recombinant Proteins; Survival Rate; Tamoxifen; Treatment Outcome | 1997 |
Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Tamoxifen | 1998 |
Interferon-alpha and chemohormonal therapy for patients with advanced melanoma: final results of a phase I-II study of the Cancer Biotherapy Research Group and the Mid-Atlantic Oncology Program.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Female; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Lung Neoplasms; Male; Melanoma; Middle Aged; Recombinant Proteins; Tamoxifen | 1998 |
Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Flow Cytometry; Humans; Interferon-alpha; Interleukin-2; Killer Cells, Natural; Lymphocyte Activation; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; T-Lymphocytes; Tamoxifen; Treatment Outcome | 1998 |
Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group st
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Recombinant Proteins; Survival Rate; Tamoxifen; Treatment Failure | 1998 |
Combined treatment with dacarbazine, cisplatin, fotemustine and tamoxifen in metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Humans; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Survival Rate; Tamoxifen | 1998 |
Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Prognosis; Risk; Survival Analysis; Tamoxifen; Treatment Outcome | 1998 |
Sustained complete remission after chemobiohormonal therapy for metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Interferon-alpha; Lung Neoplasms; Male; Melanoma; Middle Aged; Prospective Studies; Remission Induction; Skin Neoplasms; Tamoxifen | 1999 |
Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Prospective Studies; Recombinant Proteins; Remission Induction; Tamoxifen | 1999 |
A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; Disease Progression; Female; Humans; Male; Melanoma; Middle Aged; Survival Rate; Tamoxifen; Treatment Outcome | 1999 |
Phase II trial of biochemotherapy with interferon alpha, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Southwestern United States; Tamoxifen; Treatment Outcome | 1999 |
Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Disease-Free Survival; Eye Neoplasms; Female; Humans; Male; Melanoma; Middle Aged; Prospective Studies; Skin Neoplasms; Survival Rate; Tamoxifen; Treatment Outcome | 1999 |
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Skin Neoplasms; Survival Analysis; Tamoxifen; Treatment Outcome | 1999 |
Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Survival Rate; Tamoxifen; Treatment Outcome; Vindesine | 1999 |
A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Analysis; Tamoxifen; Treatment Outcome | 2000 |
Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Survival Analysis; Tamoxifen | 2000 |
GM-CSF with biochemotherapy (cisplatin, DTIC, tamoxifen, IL-2 and interferon-alpha): a phase I trial in melanoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Dacarbazine; Dose-Response Relationship, Drug; Drug Evaluation; Feasibility Studies; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Analysis; Tamoxifen; Treatment Outcome | 2000 |
Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Survival Rate; Tamoxifen | 2000 |
Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Middle Aged; Tamoxifen; Time Factors; Treatment Outcome | 2001 |
Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Prospective Studies; Skin Neoplasms; Tamoxifen; Treatment Outcome | 2002 |
Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Drug Eruptions; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hyperthyroidism; Immunologic Factors; Interleukin-2; Life Tables; Melanoma; Neoplasm Metastasis; Prospective Studies; Remission Induction; Survival Analysis; Tamoxifen; Thrombocytopenia; Treatment Outcome; Vinblastine | 2002 |
Chemoimmunohormonal therapy with carmustine, dacarbazine, cisplatin, tamoxifen, and interferon for metastatic melanoma: a prospective phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Prospective Studies; Recombinant Proteins; Remission Induction; Survival Analysis; Tamoxifen | 2002 |
Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen, or vindesine plus tamoxifen: a prospective randomized study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Skin Neoplasms; Survival Rate; Tamoxifen; Treatment Outcome; Vindesine | 2003 |
Low molecular weight heparin treatment for malignant melanoma: a pilot clinical trial.
Topics: Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Dacarbazine; Enoxaparin; Feasibility Studies; Glycosaminoglycans; Humans; Melanoma; Neoplasm Staging; Pilot Projects; Radiotherapy, Adjuvant; Remission Induction; Survival Analysis; Tamoxifen; Treatment Outcome | 2003 |
Low-dose continuous chemotherapy for metastatic melanoma: a phase II trial.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chlorambucil; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Injections, Subcutaneous; Lomustine; Male; Melanoma; Methotrexate; Middle Aged; Neoplasm Metastasis; Prognosis; Tamoxifen; Time Factors; Treatment Outcome; Vinblastine | 2003 |
[Chemotherapy in combination with laser coagulation or interstitial hyperthermia--effective combined therapy for disseminated skin melanoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Extracellular Space; Female; Humans; Hyperthermia, Induced; Laser Coagulation; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Analysis; Tamoxifen; Treatment Outcome | 2003 |
Phase II study of concurrent continuous Temozolomide (TMZ) and Tamoxifen (TMX) for recurrent malignant astrocytic gliomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Survival Rate; Tamoxifen; Temozolomide; Treatment Outcome | 2004 |
Cyclosporine A, alpha-lnterferon and interleukin-2 following chemotherapy with BCNU, DTIC, cisplatin, and tamoxifen: a phase II study in advanced melanoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cyclosporine; Dacarbazine; Female; Humans; Immunosuppressive Agents; Interferon-alpha; Interleukin-2; Male; Melanoma; Skin Neoplasms; Tamoxifen; Treatment Outcome | 2005 |
Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; DNA Methylation; DNA, Neoplasm; Drug Administration Schedule; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Odds Ratio; Predictive Value of Tests; Prognosis; Recombinant Proteins; Skin Neoplasms; Survival Analysis; Tamoxifen; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Vinblastine | 2005 |
Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Cohort Studies; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Glioma; Humans; Karnofsky Performance Status; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase C; Survival Rate; Tamoxifen; Temozolomide; Thrombocytopenia; Venous Thrombosis; Young Adult | 2012 |
Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; O(6)-Methylguanine-DNA Methyltransferase; Tamoxifen; Temozolomide; Treatment Outcome | 2013 |
Clinical observation of three dimensional conformal radiotherapy with tamoxifen in treatment of postoperative malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Male; Middle Aged; Postoperative Period; Radiotherapy, Conformal; Random Allocation; Survival Rate; Tamoxifen; Temozolomide; Thromboembolism; Treatment Outcome; Young Adult | 2015 |
50 other study(ies) available for dacarbazine and tamoxifen
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Modulation of cisplatin resistance in human malignant melanoma cells.
Topics: Carboplatin; Cisplatin; Dacarbazine; DNA; Drug Resistance; Drug Synergism; Humans; Melanoma; Metallothionein; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Tumor Cells, Cultured | 1992 |
Adjuvant chemotherapy in malignant melanoma using dacarbazine, carmustine, cisplatin, and tamoxifen: a University of South Florida and H. Lee Moffitt Melanoma Center Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Female; Florida; Follow-Up Studies; Hospitals, University; Humans; Lymph Node Excision; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Skin Neoplasms; Survival Rate; Tamoxifen | 1992 |
Treatment of stage IV malignant melanoma with dacarbazine, carmustine, cisplatin, and tamoxifen regimens: a University of South Florida and H. Lee Moffitt Melanoma Center Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Florida; Follow-Up Studies; Hospitals, University; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Survival Analysis; Survival Rate; Tamoxifen | 1992 |
New approaches to the chemotherapy of melanoma.
Topics: Alkaloids; Amifostine; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Cisplatin; Cyclophosphamide; Dacarbazine; Daunorubicin; Humans; Lomustine; Melanoma; Nitrosourea Compounds; Paclitaxel; Procarbazine; Tamoxifen; Taurine; Thiotepa; Vincristine; Vindesine | 1991 |
Malignant melanoma: primary presentation in bone marrow and lymph node.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carmustine; Cisplatin; Dacarbazine; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Tamoxifen | 1992 |
Effective chemotherapy for melanoma after treatment with interleukin-2.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Remission Induction; Tamoxifen | 1992 |
Sequential chemoimmunotherapy for metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Carmustine; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Rate; Tamoxifen; Thrombocytopenia | 1991 |
The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Hematologic Diseases; Humans; Male; Melanoma; Middle Aged; Pulmonary Embolism; Skin Neoplasms; Tamoxifen; Thrombophlebitis | 1989 |
Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Kidney Diseases; Leukopenia; Male; Melanoma; Middle Aged; Nausea; Pulmonary Embolism; Skin Neoplasms; Tamoxifen; Thrombocytopenia; Thromboembolism; Vomiting | 1987 |
[Chemotherapy of malignant melanoma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Dacarbazine; Humans; Melanoma; Neoplasm Metastasis; Prognosis; Skin Neoplasms; Tamoxifen | 1986 |
Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Tamoxifen | 1984 |
Three-drug combination of cisplatin, dacarbazine, and tamoxifen in metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Remission Induction; Tamoxifen | 1995 |
Modification of the effect of tamoxifen, cis-platin, DTIC, and interferon-alpha 2b on human melanoma cells in culture by a mixture of vitamins.
Topics: Ascorbic Acid; beta Carotene; Carotenoids; Cell Division; Cisplatin; Dacarbazine; Drug Screening Assays, Antitumor; Humans; Interferon alpha-2; Interferon-alpha; Isotretinoin; Melanoma; Recombinant Proteins; Tamoxifen; Tocopherols; Tumor Cells, Cultured; Vitamin E; Vitamins | 1994 |
Combination chemotherapy of metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Humans; Melanoma; Neoplasm Metastasis; Tamoxifen | 1995 |
Antiphospholipid syndrome associated with immunotherapy for patients with melanoma.
Topics: Adult; Aged; Antibodies, Antinuclear; Antibodies, Antiphospholipid; Antineoplastic Combined Chemotherapy Protocols; Antiphospholipid Syndrome; Autoantibodies; Cardiolipins; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Female; Humans; Immunoglobulin G; Immunotherapy; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Tamoxifen; Thromboembolism | 1994 |
The chemohormonal therapy of metastatic melanoma: possible benefit of tamoxifen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Tamoxifen; Thrombophlebitis | 1993 |
Tamoxifen and chemotherapy for refractory metastatic malignant melanoma.
Topics: Adult; Antineoplastic Agents; Cisplatin; Dacarbazine; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Tamoxifen | 1993 |
Urinary excretion of proteolyzed alpha1-antitrypsin: specificity, quantitation, and relation to therapy response in patients with acute myeloid leukemia.
Topics: Adult; Aged; alpha 1-Antitrypsin; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blast Crisis; Bleomycin; Bone Marrow; Cyclophosphamide; Dacarbazine; Danazol; Disease-Free Survival; Doxorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Nimustine; Peptide Fragments; Prednisone; Probability; Procarbazine; Prognosis; Proteinuria; Recurrence; Remission Induction; Reproducibility of Results; Tamoxifen; Time Factors; Vincristine | 1995 |
Primary malignant melanoma of the esophagus: report of a case successfully treated with pre- and post-operative adjuvant hormone-chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Esophageal Neoplasms; Esophagectomy; Humans; Lymph Node Excision; Male; Melanoma; Middle Aged; Nimustine; Tamoxifen | 1998 |
[Chemotherapy of malignant melanoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Dacarbazine; Humans; Immunotherapy; Interleukins; Lomustine; Melanoma; Middle Aged; Palliative Care; Skin Neoplasms; Tamoxifen; Vincristine | 1998 |
Dacarbazine, nimustine hydrochloride, cisplatin and tamoxifen combination chemotherapy for advanced malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nimustine; Skin Neoplasms; Tamoxifen; Tomography, X-Ray Computed; Treatment Outcome | 1999 |
Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease-Free Survival; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Pilot Projects; Skin Diseases; Skin Neoplasms; Tamoxifen; Vinblastine | 1999 |
Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Dacarbazine; Humans; Melanoma; Neoplasm Metastasis; Retrospective Studies; Survival Analysis; Tamoxifen; Treatment Outcome | 2000 |
What can we learn from phase II adjuvant trials in melanoma?
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Controlled Clinical Trials as Topic; Dacarbazine; Drug Synergism; Humans; Immunologic Factors; Interferons; Interleukin-2; Melanoma; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Research Design; Skin Neoplasms; Tamoxifen; Treatment Outcome; Vinblastine | 2000 |
[Diagnostic problems due to alternative medicine].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Breast Neoplasms; Dacarbazine; Diagnosis, Differential; Doxorubicin; Female; Hodgkin Disease; Humans; Mechlorethamine; Prednisone; Procarbazine; Radiography; Skin; Tamoxifen; Vinblastine; Vincristine | 2000 |
Identification of novel enzyme-prodrug combinations for use in cytochrome P450-based gene therapy for cancer.
Topics: Animals; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Coculture Techniques; Cyclophosphamide; Cytochrome P-450 Enzyme System; Dacarbazine; Dose-Response Relationship, Drug; Doxorubicin; Enzyme Activation; Female; Genetic Therapy; Ifosfamide; Inhibitory Concentration 50; Ketoconazole; Liver; Male; Microsomes, Liver; Models, Chemical; Neoplasms; Procarbazine; Prodrugs; Rats; Tamoxifen; Time Factors; Troleandomycin; Tumor Cells, Cultured | 2003 |
Synchronous cancer and metastatic melanoma of the breasts.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Cisplatin; Dacarbazine; Female; Humans; Mammography; Melanoma; Retroperitoneal Neoplasms; Tamoxifen | 2004 |
Response of recurrent anaplastic ependymoma to a combination of tamoxifen and isotretinoin.
Topics: Adrenal Cortex Hormones; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Carboplatin; Carmustine; Dacarbazine; Disease Progression; Dose Fractionation, Radiation; Ependymoma; Gadolinium; Headache; Humans; Isotretinoin; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Remission Induction; Tamoxifen; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Follow-Up Studies; Humans; Interferon-alpha; Interleukin-2; Male; Medical Records; Melanoma; Middle Aged; Mucous Membrane; Retrospective Studies; Skin Neoplasms; Survival Rate; Tamoxifen; Temozolomide; Treatment Outcome; Vaginal Neoplasms; Vinblastine; Vulvar Neoplasms | 2004 |
Acute myocardial infarction induced by cisplatin-based combination chemotherapy for malignant melanoma: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Calcinosis; Cisplatin; Coronary Artery Disease; Dacarbazine; Drug Administration Schedule; Female; Humans; Melanoma; Middle Aged; Myocardial Infarction; Nimustine; Skin Neoplasms; Tamoxifen | 2006 |
Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin.
Topics: Animals; Anthracenes; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Dacarbazine; Disease Models, Animal; Down-Regulation; Drug Synergism; Glioblastoma; Growth Inhibitors; Humans; Male; Mice; Mice, Nude; Perylene; Tamoxifen; Temozolomide; Transplantation, Heterologous; Treatment Outcome | 2006 |
Microphthalmos associated with Dartmouth combination chemotherapy in pregnancy: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Infant, Newborn; Liver Neoplasms; Male; Melanoma; Microphthalmos; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, First; Pregnancy Trimester, Second; Skin Neoplasms; Tamoxifen | 2007 |
Dacarbazine-Doxorubicin therapy ameliorated an extremely aggressive mesenteric desmoid tumor associated with familial adenomatous polyposis: report of a case.
Topics: Adenomatous Polyposis Coli; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dacarbazine; Doxorubicin; Fibromatosis, Aggressive; Humans; Imatinib Mesylate; Male; Mesentery; Neoplasm Recurrence, Local; Peritoneal Neoplasms; Piperazines; Pyrimidines; Remission Induction; Tamoxifen | 2008 |
Antitumor efficacy testing in rodents.
Topics: Animals; Antineoplastic Agents; Biological Availability; Dacarbazine; Data Interpretation, Statistical; Drug Approval; Drug Design; Drug Screening Assays, Antitumor; Drugs, Investigational; Endpoint Determination; Humans; Kaplan-Meier Estimate; Mice; Neoplasms; Pharmaceutical Vehicles; Random Allocation; Rats; Research Design; Rodentia; Sample Size; Tamoxifen; Temozolomide; Topotecan; Transplantation, Heterologous; United States | 2008 |
[Combined treatment with dacarbazine, nimustine, cisplatin, and tamoxifen plus interferon-beta in a patient with advanced anorectal malignant melanoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cisplatin; Dacarbazine; Humans; Interferon-beta; Liver Neoplasms; Male; Melanoma; Neoplasm Staging; Nimustine; Rectal Neoplasms; Tamoxifen; Treatment Outcome | 2008 |
Intra-axial brainstem malignant melanoma mimicking cavernous angioma--case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cranial Nerve Diseases; Craniotomy; Dacarbazine; Diagnosis, Differential; Female; Hemangioma, Cavernous, Central Nervous System; Humans; Intracranial Hemorrhages; Magnetic Resonance Imaging; Melanoma; Nimustine; Radiotherapy, Adjuvant; Reoperation; Tamoxifen | 2008 |
Malignant melanoma of the breast: N-isopropyl-p-(123) I-iodoamphetamine single photon emission computed tomography ((123) I-IMP SPECT) is useful for the detection of metastasis.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cisplatin; Dacarbazine; Fatal Outcome; Female; Humans; Interferon-beta; Iofetamine; Liver Neoplasms; Lung Neoplasms; MART-1 Antigen; Mastectomy, Modified Radical; Melanoma; Middle Aged; Neoplasm Staging; Nimustine; Nipples; Radiopharmaceuticals; S100 Proteins; Skin Neoplasms; Tamoxifen; Tomography, Emission-Computed, Single-Photon; Vincristine | 2010 |
Re-evaluation of cytostatic therapies for meningiomas in vitro.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Humans; Hydroxyurea; Losartan; Meningeal Neoplasms; Meningioma; Metformin; Mifepristone; Neurofibromin 2; Promoter Regions, Genetic; Quinazolines; Radiation Tolerance; Tamoxifen; Temozolomide; Tumor Suppressor Proteins; Verapamil | 2014 |
Chemotherapeutic effect of tamoxifen on temozolomide-resistant gliomas.
Topics: Animals; Antineoplastic Agents, Hormonal; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Electron Transport Complex I; Glioma; Humans; Male; Methylation; Mitochondria; Promoter Regions, Genetic; Rats, Sprague-Dawley; Tamoxifen; Temozolomide; Tumor Suppressor Proteins | 2015 |
Tamoxifen in combination with temozolomide induce a synergistic inhibition of PKC-pan in GBM cell lines.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Glioblastoma; Humans; Phosphorylation; Protein Kinase C; Tamoxifen; Temozolomide | 2015 |
Glioblastoma entities express subtle differences in molecular composition and response to treatment.
Topics: Apoptosis; Astrocytoma; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genetic Heterogeneity; Glioblastoma; Humans; Neoplasm Grading; Protein Kinase C; Signal Transduction; Tamoxifen; Temozolomide | 2017 |